J Craig Venter Institute Inc.
J Craig Venter Institute Inc.
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for J Craig Venter Institute Inc.? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
A NON-PROFIT RESEARCH INSTITUTE DEDICATED TO THE ADVANCEMENT OF THE SCIENCE OF GENOMICS, UNDERSTANDING THE IMPLICATIONS FOR SOCIETY, AND COMMUNICATION OF RESULTS TO SCIENTIFIC COMMUNITIES, THE PUBLIC, AND POLICYMAKERS.
About
DEPARTMENT OF HEALTH AND HUMAN SERVICESDURING 2018, JCVI HAD MULTIPLE ACTIVE RESEARCH GRANTS AND CONTRACTS FROM AGENCIES WITHIN THE DHHS. AMONG THESE WAS JCVI'S LARGEST FUNDED RESEARCH PROGRAM, A GRANT FROM THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID/NIH) TO SERVE AS A DESIGNATED GENOME CENTER FOR INFECTIOUS DISEASES (GCID). THE GCID PROGRAM SCOPE INCLUDES ANALYSIS OF VIRAL, BACTERIAL, AND PARASITE PATHOGENS. THE BACTERIAL AND PARASITE PROGRAMS HAVE A PARTICULAR EMPHASES ON ANTIMICROBIAL RESISTANCE. THE BACTERIAL PROGRAM IS FOCUSED ON THE EVOLUTION AND TRANSMISSION OF CARBAPENEM-RESISTANT ENTEROBACTERIACEAE AND OTHER GRAM-NEGATIVE BACTERIA. ALL GENOME SEQUENCE DATA PRODUCED WITH GCID FUNDING IS RAPIDLY DEPOSITED IN PUBLIC REPOSITORIES TO PROMOTE THE WIDEST POSSIBLE USE AMONG RESEARCH SCIENTISTS. JCVI IS THE PRIMARY LEAD OF A LARGE COLLABORATIVE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS/NIH) U01 AWARD WITH THE GOAL TO DEVELOP, VALIDATE AND DISSEMINATE A COMPUTATIONAL INFRASTRUCTURE FOR UNBIASED ANALYSIS OF CYTOMETRY DATA FOR BOTH DIAGNOSTIC AND DISCOVERY APPLICATIONS THAT COULD HELP OVERCOME THE CURRENT LIMITATIONS OF MANUAL ANALYSIS AND PROVIDE FOR MORE EFFICIENT, OBJECTIVE, ACCURATE, AND REPRODUCIBLE ANALYSIS OF CYTOMETRY DATA. FLOW CYTOMETRY ANALYSIS IS WIDELY USED IN TRANSLATIONAL RESEARCH LAB TO EXPLORE THE MECHANISMS OF NORMAL AND ABNORMAL BIOLOGICAL PROCESSES AND IN THE CLINICAL DIAGNOSTIC LAB FOR THE IDENTIFICATION AND CLASSIFICATION OF BLOOD-BORNE MALIGNANCIES. HOWEVER, THE CURRENT PRACTICE FOR CYTOMETRY DATA ANALYSIS RELIES ON SUBJECTIVE AND AD HOC "MANUAL GATING". DURING THE YEAR OF 2018, THE PROJECT TEAM OF JCVI, THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (UCSD), THE UNIVERSITY OF CALIFORNIA, IRVINE (UCI), AND STANFORD UNIVERSITY COLLABORATED TO CONTINUE IMPROVING THE ACCESSIBILITY, FUNCTIONALITY, AND USABILITY OF THE PROPOSED INFRASTRUCTURE. THE PROJECT TEAMS ASSEMBLED MULTIPLE FLOW CYTOMETRY DATASETS FROM IMPORTANT BIOMEDICAL PROJECTS CONDUCTED BY TRANSLATIONAL RESEARCHERS AT UC IRVINE AND FROM THE CLINICAL DIAGNOSTICS LAB AT UCSD. THE JCVI TEAM PROCESSED AND ANALYZED THE DATASETS USING THE COMPUTATIONAL INFRASTRUCTURE AND VALIDATED THE ANALYSIS RESULTS USING FOLLOW-UP STUDIES. THE COMPUTATIONAL ANALYSES OF THESE DATASETS HAVE IDENTIFIED NOVEL CELL SUBSETS FROM HUMAN LEUKOCYTES FOR INDEPENDENT ASTHMA RESEARCH PROJECTS BEING CONDUCTED AT PEDIATRICS OF UC IRVINE. THE ANALYSES HAVE ALSO IDENTIFIED A NOVEL COMBINATION OF CELL SURFACE MARKERS FOR PRECISION DIAGNOSIS OF THE CHRONIC LYMPHOCYTIC LEUKEMIA BASED ON THE CLINICAL FLOW CYTOMETRY DATA PROVIDED BY UCSD. THE RESULTS AND FINDINGS HAVE BEEN PUBLISHED ON PEER-REVIEWED JOURNALS OR REPORTED AT SCIENTIFIC CONFERENCES. THE PROJECT TEAM HAVE ALSO BEEN TRAINING THE TRANSLATIONAL RESEARCHERS OF UCI PEDIATRICS AND HEMATOPATHOLOGISTS OF UCSD PATHOLOGY FOR USING THE ADVANCED DATA ANALYTICS TOOLS ON THE COMPUTATIONAL INFRASTRUCTURE THROUGH IN-PERSON SITE VISITS AND WEBEX MEETINGS.ANTIBIOTIC RESISTANCE IS ONE OF THE BIGGEST PUBLIC HEALTH PROBLEMS OF OUR TIME. JCVI IN COLLABORATION WITH NORTHEASTERN UNIVERSITY HAVE DEVELOPED NEW METHODS TO GROW AND EXPLOIT PREVIOUSLY UNCHARACTERIZED MICROBES. JCVI HAS DEVELOPED A TRANSCRIPTION-BASED PLATFORM THAT BIOINFORMATICALLY PREDICTS WHETHER NEW POTENTIAL COMPOUNDS ARE EXPRESSING ANTIBIOTIC PROPERTIES WITH NOVEL MECHANISMS OF ACTION. PROMISING COMPOUNDS ARE VALIDATED AND BECOME LEAD ANTIMICROBIAL COMPOUNDS FOR FURTHER STUDY. JCVI, IN COLLABORATION WITH NORTHROP GRUMMAN, SERVES AS THE MAIN DEVELOPER OF THE VIRAL PATHOGEN RESOURCE (WWW.VIPRBRC.ORG) AND THE INFLUENZA RESEARCH DATABASE (WWW.FLUDB.ORG). THESE RESOURCES SERVE AS FREE PUBLIC PORTALS TO A WIDE RANGE OF INFORMATION, DATA, AND ANALYTICAL TOOLS FOR INTERPRETING VIRAL GENOMES IN THE CONTEXT OF DISEASE. OVER 3000 RESEARCHERS THROUGHOUT THE WORLD USE THESE RESOURCES EVERY WEEK. SEVERAL ADDITIONAL DHHS GRANTS AT JCVI ARE RELATED TO HUMAN MICROBIOME STUDIES. THE MICROBIOME IS THE COLLECTION OF MICROBES THAT LIVE IN AND ON THE HUMAN BODY; THESE SPECIES HAVE RECEIVED CONSIDERABLE ATTENTION IN RECENT YEARS BECAUSE A NEW APPRECIATION OF THE COMPLEX ROLES THAT THEY PLAY IN HEALTH AND DISEASE. SOME OF THESE STUDIES ARE AIMED AT BASIC CHARACTERIZATION OF THE COMPOSITION AND ACTIVITY OF THE MICROBIOME, WHILE OTHERS SEEK TO UNDERSTAND THE CONTRIBUTION OF THE MICROBIOME TO THE DEVELOPMENT OF VARIOUS DISEASES INCLUDING ALCOHOLIC HEPATITIS, TYPE 1 DIABETES, DENTAL CARIES, DIARRHEA, AND ESOPHAGEAL CANCER, AMONG OTHERS. IN COLLABORATION WITH THE SANFORD BURNHAM PREBYS INSTITUTE, THE JCVI IS DEVELOPING METHODS TO IDENTIFY NEW DRUGS THAT SPECIFICALLY TARGET AN ENZYME IN THE MALARIA PARASITE THAT WE KNOW IS ESSENTIAL FOR THE GROWTH OF THE PARASITE. MALARIA, A PARASITIC DISEASE TRANSMITTED BY MOSQUITOES, IS STILL A MAJOR THREAT TO PUBLIC HEALTH AND ECONOMIC DEVELOPMENT IN THE TROPICAL AND SUB-TROPICAL REGIONS OF THE GLOBE, AS WELL AS TO TRAVELERS TO THESE AREAS FROM THE DEVELOPED WORLD. CONTINUAL DEVELOPMENT OF NEW DRUGS AND VACCINES IS ESSENTIAL TO ENSURE THAT MALARIA CONTROL IS MAINTAINED TO PREVENT UNNECESSARY ILLNESS AND LOSS OF LIFE. THIS PROJECT HAS SHOWN THAT ONE PARTICULAR CHEMICAL THAT BLOCKS THIS ENZYME CAN KILL MALARIA PARASITES IN THE LABORATORY. THIS COLLABORATION IS NOW DEVELOPING A LABORATORY TEST THAT WE CAN USE TO SCREEN THOUSANDS OF CHEMICALS TO FIND THOSE THAT ARE MORE EFFECTIVE AT KILLING MALARIA PARASITES THAN THE FIRST CHEMICAL. THE INSTITUTE ALSO PARTICIPATES IN THE H3AFRICA PROGRAM VIA A COLLABORATION THE UNIVERSITY OF CAPE TOWN, SOUTH AFRICA, TO TRAIN COLLABORATORS IN HUMAN MICROBIOME ANALYSIS. THE PROGRAM IS SPONSORED BY THE NIH COMMON FUND TO BRING TECHNOLOGICAL RESOURCES AND TRAINING IN A CAPITAL INVESTMENT-INTENSIVE FIELD (GENOMICS) TO THE AFRICAN CONTINENT VIA COLLABORATIONS WITH US SCIENTISTS WITH EXPERTISE IN THIS FIELD.
Interesting data from their 2020 990 filing
According to the filing documents, the non-profit's mission is defined as “A non-profit research institute dedicated to the advancement of the science of genomics, understanding the implications for society, and communication of results to scientific communities, the public, and policymakers.”.
When referring to its tasks, they were referred to as: “A non-profit research institute dedicated to the advancement of the science of genomics, understanding the implications for society, and communication of results to scientific communities, the public, and policymakers.”.
- The non-profit's state of operation has been legally reported as MD.
- According to the latest filing, the non-profit's address in 2020 is 4120 CAPRICORN LANE, LA JOLLA, CA, 92037.
- The total number of employees reported by the non-profit on their form for 2020 is 225.
- Is not a private foundation.
- Expenses are greater than $1,000,000.
- Revenue is greater than $1,000,000.
- Revenue less expenses is $6,391,587.
- The organization has 7 independent voting members.
- The organization was formed in 1993.
- The organization pays $22,035,831 in salary, compensation, and benefits to its employees.
- The organization pays $304,484 in fundraising expenses.